Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm A Smith

Showing results (61-70 of 188) with videos related to

Pageof 19
Sort By:
Pediatric Blood & Cancer|May 18, 2019
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft modelsRaushan T Kurmasheva, Abhik Bandyopadhyay, Edward Favours, et al.
Pediatric Blood & Cancer|March 2, 2011
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing programMalcolm A Smith, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|February 9, 2008
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Pediatric Blood & Cancer|July 20, 2007
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, E Anders Kolb, et al.
Pediatric Blood & Cancer|June 8, 2007
Initial testing of cisplatin by the pediatric preclinical testing programMimi Tajbakhsh, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer|August 19, 2014
Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing programPeter J Houghton, Raushan T Kurmasheva, Dmitry Lyalin, et al.
Pediatric Blood & Cancer|April 26, 2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer|July 25, 2020
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortiumJonathan Gill, Wendong Zhang, Zhongting Zhang, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.
Pediatric Blood & Cancer|October 5, 2007
Initial testing of dasatinib by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Pageof 19

Showing results (61-70 of 188) with videos related to

Sort By:
Pageof 19
Pediatric Blood & Cancer|May 18, 2019
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft modelsRaushan T Kurmasheva, Abhik Bandyopadhyay, Edward Favours, et al.
Pediatric Blood & Cancer|March 2, 2011
Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing programMalcolm A Smith, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|February 9, 2008
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Pediatric Blood & Cancer|July 20, 2007
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, E Anders Kolb, et al.
Pediatric Blood & Cancer|June 8, 2007
Initial testing of cisplatin by the pediatric preclinical testing programMimi Tajbakhsh, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer|August 19, 2014
Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing programPeter J Houghton, Raushan T Kurmasheva, Dmitry Lyalin, et al.
Pediatric Blood & Cancer|April 26, 2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer|July 25, 2020
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortiumJonathan Gill, Wendong Zhang, Zhongting Zhang, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2016
Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapyAraz Marachelian, Ami Desai, Frank Balis, et al.
Pediatric Blood & Cancer|October 5, 2007
Initial testing of dasatinib by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Pageof 19